文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Biomaterial-based vascularization strategies for enhanced treatment of peripheral arterial disease.

作者信息

Wang Haojie, Lin Fuxin, Zhang Yibin, Lin Yuanxiang, Gao Bin, Kang Dezhi

机构信息

Department of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, China.

Fujian Provincial Institutes of Brain Disorders and Brain Sciences, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, China.

出版信息

J Nanobiotechnology. 2025 Feb 12;23(1):103. doi: 10.1186/s12951-025-03140-4.


DOI:10.1186/s12951-025-03140-4
PMID:39940018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11823048/
Abstract

Peripheral arterial disease (PAD) poses a global health challenge, particularly in its advanced stages known as critical limb ischemia (CLI). Conventional treatments often fail to achieve satisfactory outcomes. Patients with CLI face high rates of morbidity and mortality, underscoring the urgent need for innovative therapeutic strategies. Recent advancements in biomaterials and biotechnology have positioned biomaterial-based vascularization strategies as promising approaches to improve blood perfusion and ameliorate ischemic conditions in affected tissues. These materials have shown potential to enhance therapeutic outcomes while mitigating toxicity concerns. This work summarizes the current status of PAD and highlights emerging biomaterial-based strategies for its treatment, focusing on functional genes, cells, proteins, and metal ions, as well as their delivery and controlled release systems. Additionally, the limitations associated with these approaches are discussed. This review provides a framework for designing therapeutic biomaterials and offers insights into their potential for clinical translation, contributing to the advancement of PAD treatments.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/631dbcd5fcc9/12951_2025_3140_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/9599fc109a69/12951_2025_3140_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/e312f1b36880/12951_2025_3140_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/6439a0a85026/12951_2025_3140_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/67d072c46ff6/12951_2025_3140_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/733a15257ed6/12951_2025_3140_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/34a7412bc9f0/12951_2025_3140_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/6145963dccf8/12951_2025_3140_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/54921db81eed/12951_2025_3140_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/e87e2cbdc8f7/12951_2025_3140_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/77b97bef2be7/12951_2025_3140_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/631dbcd5fcc9/12951_2025_3140_Fig11_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/9599fc109a69/12951_2025_3140_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/e312f1b36880/12951_2025_3140_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/6439a0a85026/12951_2025_3140_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/67d072c46ff6/12951_2025_3140_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/733a15257ed6/12951_2025_3140_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/34a7412bc9f0/12951_2025_3140_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/6145963dccf8/12951_2025_3140_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/54921db81eed/12951_2025_3140_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/e87e2cbdc8f7/12951_2025_3140_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/77b97bef2be7/12951_2025_3140_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5508/11823048/631dbcd5fcc9/12951_2025_3140_Fig11_HTML.jpg

相似文献

[1]
Biomaterial-based vascularization strategies for enhanced treatment of peripheral arterial disease.

J Nanobiotechnology. 2025-2-12

[2]
Hydrogel-based therapeutic angiogenesis: An alternative treatment strategy for critical limb ischemia.

Biomaterials. 2021-7

[3]
Antioxidative and Angiogenic Hyaluronic Acid-Based Hydrogel for the Treatment of Peripheral Artery Disease.

ACS Appl Mater Interfaces. 2021-9-29

[4]
Engineered systems for therapeutic angiogenesis.

Curr Opin Pharmacol. 2017-8-12

[5]
Therapeutic Biomaterial Approaches to Alleviate Chronic Limb Threatening Ischemia.

Adv Sci (Weinh). 2021-2-8

[6]
Therapeutic angiogenesis using zinc oxide nanoflowers for the treatment of hind limb ischemia in a rat model.

Biomed Mater. 2021-3-26

[7]
Concise review: injectable biomaterials for the treatment of myocardial infarction and peripheral artery disease: translational challenges and progress.

Stem Cells Transl Med. 2014-9

[8]
Therapeutic angiogenesis-based strategy for peripheral artery disease.

Theranostics. 2022

[9]
A computational analysis of pro-angiogenic therapies for peripheral artery disease.

Integr Biol (Camb). 2018-1-22

[10]
Emerging trends in nationwide mortality, limb loss, and resource utilization for critical limb ischemia in young adults.

Cardiovasc Revasc Med. 2024-10

本文引用的文献

[1]
Bioengineered Human Arteries for the Repair of Vascular Injuries.

JAMA Surg. 2025-2-1

[2]
Synthetic Antiangiogenic Vascular Endothelial Growth Factor-A Splice Variant Revascularizes Ischemic Muscle in Peripheral Artery Disease.

J Am Heart Assoc. 2024-10-15

[3]
Illness Trajectories After Revascularization in Patients With Peripheral Artery Disease: A Unified Approach to Understanding the Risk of Major Amputation and Death.

Circulation. 2024-7-23

[4]
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions.

Signal Transduct Target Ther. 2024-7-1

[5]
Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial.

Nat Commun. 2024-6-13

[6]
Pro-angiogenic Terbium Hydroxide Nanorods Improve Critical Limb Ischemia in Part by Amelioration of Ischemia-Induced Endothelial Injury.

ACS Appl Bio Mater. 2024-7-15

[7]
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

J Am Coll Cardiol. 2024-6-18

[8]
Harnessing the potential of monocytes/macrophages to regenerate tissue-engineered vascular grafts.

Cardiovasc Res. 2024-7-2

[9]
Chronic limb-threatening ischemia with no revascularization option: Result from a multidisciplinary care model.

Eur J Intern Med. 2024-7

[10]
Diversity in randomized clinical trials for peripheral artery disease: a systematic review.

Int J Equity Health. 2024-2-13

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索